^
Association details:
Biomarker:No biomarker
Cancer:Marginal Zone Lymphoma
Drug:Kymriah (tisagenlecleucel-T) (CD19-targeted CAR-T immunotherapy)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Marginal Zone Lymphoma: Suggested treatment regimens…Anti-CD19 CAR T-cell therapy (only after ≥2 prior chemoimmunotherapy regimens…Tisagenlecleucel